Get an HCM second opinion before choosing the next medication, procedure, or device.

A second opinion can be useful when the diagnosis or phenotype remains uncertain, symptoms and resting tests do not align, a new medication or septal reduction procedure has been proposed, myectomy and alcohol septal ablation are being compared, mitral-valve treatment is under discussion, or sudden-death risk and an ICD decision feel unresolved. It should not delay urgent or time-sensitive care directed by your treating team.

In obstructive HCM, blood leaving the left ventricle encounters a dynamic outflow obstruction, often involving the septum and systolic anterior motion of the mitral valve. In nonobstructive HCM, hypertrophy is present without that outflow gradient under the conditions tested. Symptoms and treatment questions can occur in either phenotype, and obstruction may require provocation or exercise to detect.

Yes, when that is the decision documented in the record. The report can organize prior medication trials, symptoms, gradients, anatomy, functional testing, comorbidities, and the reasons continued medical therapy, a myosin inhibitor, disopyramide, myectomy, alcohol septal ablation, or further evaluation may be under discussion. It does not prescribe a drug or select a procedure.

Myectomy is open-heart surgery that removes part of the thickened septum and can address associated mitral, subvalvular, coronary, or other cardiac disease when needed. Alcohol septal ablation is a catheter-based procedure that uses a selected septal artery to reduce tissue causing obstruction. Anatomy, age, comorbidity, associated disease, local expertise, and individual priorities affect the comparison; not every patient is a candidate for either approach.

Mitral regurgitation in HCM may result from systolic anterior motion, intrinsic leaflet disease, papillary-muscle or chordal anatomy, or more than one mechanism. The mechanism can affect whether relieving septal obstruction alone may address the leakage or whether a separate mitral strategy deserves discussion.

No. An ICD is a shared clinical decision, not an automatic result from one score or finding. The review can organize documented major risk markers and additional modifiers—including family history, syncope, wall thickness, ejection fraction, apical aneurysm, nonsustained ventricular tachycardia, and MRI scar—alongside device burdens and unanswered questions for your HCM and electrophysiology teams.

No. Current guidance uses a structured review of major risk factors and additional clinical modifiers; estimated five-year risk may add context for some patients age 16 or older. Any estimate depends on complete, accurate inputs and does not predict an individual event. Clinical judgment and shared decision-making remain essential.

Yes, when those studies are relevant and available. MRI can add anatomy and scar context, rhythm monitoring can identify atrial or ventricular arrhythmias, and exercise testing can clarify functional limitation or dynamic obstruction. The report also identifies material gaps in the available record without implying that every patient requires every test.

A cardiac surgeon and cardiologist independently review the same complete record, then confer and co-sign one WHITEGLOVE Insights™ report. Both perspectives are included at every service level. A live physician consultation is optional and costs extra.

The exact record depends on the question. It commonly includes source echocardiograms, cardiac MRI when performed, exercise or stress testing, ECGs and rhythm-monitor reports, clinical notes, medication history and response, laboratory results, family and genetic context, device records when applicable, and the proposed treatment plan. With authorization, the records team can help identify and request what is needed.

The written report is delivered within 24 hours after the records and imaging required for your review have been received and confirmed complete. Time spent requesting, transferring, or collecting records is outside that 24-hour window.

The written WHITEGLOVE Insights™ review starts at $495. A live physician consultation or concierge access can be added at higher service levels. The service is direct pay, and WHITEGLOVEMD does not submit an insurance claim.

When another specialist or center may be worth considering, the report can organize relevant HCM, myectomy, alcohol septal ablation, electrophysiology, imaging, and longitudinal-care experience, along with geography and practical fit. The team may help facilitate an introduction through its national physician and transfer network. This does not imply a formal hospital partnership or guarantee acceptance, timing, candidacy, or treatment.